TV005四价登革热疫苗在孟加拉登革热流行区的安全性及跨血清型、跨年龄组的持久免疫原性:一项随机对照试验
在孟加拉国达卡单中心开展随机、安慰剂对照、年龄递减临床试验,192名1—50岁健康志愿者按3:1随机接种单剂TV005或安慰剂并随访3年。疫苗耐受良好,第180天各年龄组对各血清型普遍血清阳性;既往登革热暴露者抗体滴度更高,1—4岁无既往暴露者中DENV 1、3、4抗体滴度3年内下降。
要点
- 单剂TV005耐受良好,多数不良事件为轻度,皮疹最常见。
- 第180天各年龄组对DENV 1—4血清阳性率分别为83%、99%、96%、87%。
- 1—4岁无既往登革热暴露者中DENV 1、3、4抗体滴度3年内下降。
核心结论
- 随访3年,单剂四价登革热疫苗TV005在幼儿至成人中耐受良好,对全部四种血清型具有免疫原性,包括无既往登革热暴露者。
研究设计与样本
- 在孟加拉国登革热流行的达卡单中心开展随机、安慰剂对照、年龄递减临床试验,技术自美国转移。
- 1—50岁健康志愿者按3:1随机(按四个年龄组分層)接受单剂TV005或安慰剂,随访3年。
- 研究为双盲,第180天揭盲;结局评估者、门诊工作人员和志愿者全程保持盲态。
- 2016年3月13日至2017年2月14日共入组192名孟加拉国志愿者,四个年龄组每组48人。
主要发现
- 皮疹为最常见的疫苗相关征集性不良事件,疫苗组37/144(26%)vs 安慰剂组6/48(12%)。
- 发热7例(144例中5%)和关节痛7例(108例中6%)仅在疫苗受种者中观察到。
- 第180天各年龄组疫苗受种者(n=142)对DENV 1血清阳性118例(83%)、DENV 2 141例(99%)、DENV 3 137例(96%)、DENV 4 124例(87%)。
- 既往登革热暴露者抗体滴度高于无既往暴露者:DENV 1均值480(SD 4.0)vs 32(2.4),DENV 2 1042(3.2)vs 105(3.1),DENV 3 1406(2.8)vs 129(4.7),DENV 4 105(3.3)vs 65(3.1),分别为10—15倍(DENV 1—3)和1.6倍(DENV 4)。
- 随访3年后多数成人(63—86%)对全部血清型抗体滴度保持稳定;1—4岁无既往暴露队列中DENV 1、3、4滴度3年内下降(DENV 2血清阳性69%,DENV 1、3、4血清阳性22—28%)。
关键数值与推荐
- 主要结局:接种后28天内征集性相关不良事件比例(按方案分析)及第180天用血清型特异性中和抗体(PRNT50 ≥10)评估的接种后血清阳性率。
- 次要结局包括病毒血症、既往登革热暴露的影响及抗体应答持久性。
- 疫苗组皮疹37/144(26%)vs 安慰剂组6/48(12%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Morbidity and mortality from dengue virus (DENV) is rapidly growing in the large populations of south Asia. Few formal evaluations of candidate dengue vaccine candidates have been undertaken in India, Pakistan, or Bangladesh. Tetravalent vaccines must be tested for safety and immunogenicity in all age groups and in those previously exposed and naive to DENV infections. TV005 is a live, attenuated tetravalent dengue vaccine. We evaluated the safety and immunogenicity of a single dose of TV005 across age groups in dengue-endemic Bangladesh. METHODS: We performed a randomised, placebo-controlled age de-escalating clinical trial of TV005 at a single clinical site in dengue-endemic Dhaka, Bangladesh, following a technology transfer from the USA. Healthy (as determined by history, clinical examination, and safety laboratory test results) volunteers aged 1-50 years were randomly assigned 3:1 (stratified by four age groups) to receive a single dose of TV005 vaccine or placebo. Participants were followed up for 3 years. The study was double blind and was unmasked at day 180; outcome assessors, clinic staff, and volunteers remained blind throughout. Primary outcomes were safety, evaluated per-protocol as proportion of volunteers with solicited related adverse events of any severity through 28 days post dosing, and post-vaccination seropositivity by day 180 using serotype-specific neutralising antibodies (PRNT50 ≥10). Secondary outcomes included viremia, impact of past dengue exposure, and durability of antibody responses. This study is registered with Clinicaltrials.gov, NCT02678455, and is complete. FINDINGS: Between March 13, 2016, and Feb 14, 2017, 192 volunteers were enrolled into four age groups (adults [18-50 years; 20 male and 28 female], adolescents [11-17 years; 27 male and 21 female], children [5-10 years; 15 male and 33 female], and young children [1-4 years; 29 male and 19 female]) with 48 participant per group. All participants were Bangladeshi. Vaccination was well tolerated and most adverse events were mild. Rash was the most common vaccine-associated solicited adverse event, in 37 (26%) of 144 vaccine recipients versus six (12%) of 48 placebo recipients; followed by fever in seven (5% of 144) and arthralgias in seven (6% of 108), which were only observed in vaccine recipients. Post-vaccine, volunteers of all ages (n=142) were seropositive to most serotypes with 118 (83%) seropositive to DENV 1, 141 (99%) to DENV 2, 137 (96%) to DENV 3, and 124 (87%) to DENV 4, overall by day 180. Post-vaccination, viraemia was not consistently found and antibody titres were higher (10-15-fold for DENV 1-3 and 1·6-fold for DENV 4) in individuals with past dengue exposure compared with the dengue-naive participants (DENV 1 mean 480 [SD 4·0] vs 32 [2·4], DENV 2 1042 [3·2] vs 105 [3·1], DENV 3 1406 [2·8] vs 129 [4·7], and DENV 4 105 [3·3] vs 65 [3·1], respectively). Antibody titres to all serotypes remained stable in most adults (63-86%) after 3 years of follow-up. However, as expected for individuals without past exposure to dengue, titres for DENV 1, 3, and 4 waned by 3 years in the youngest (1-4 year old) cohort (69% seropositive for DENV 2 and 22-28% seropositive for DENV 1, 3, and 4). INTERPRETATION: With 3 years of follow-up, the single-dose tetravalent dengue vaccine, TV005, was well tolerated and immunogenic for all four serotypes in young children to adults, including individuals with no previous dengue exposure. FUNDING: National Institutes of Health-National Institute of Allergy and Infectious Diseases Intramural Research Program and Johns Hopkins University. TRANSLATION: For the Bangla translation of the abstract see Supplementary Materials section.
引用
- Walsh MR, Alam MS, Pierce KK, et al. Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial. Lancet Infect Dis. 2023. PMID: 37776876. doi:10.1016/S1473-3099(23)00520-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。